{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.512","value":"-8.10"},{"groupId":"OG001","spread":"6.316","value":"-2.93"},{"groupId":"OG002","spread":"6.480","value":"0.51"}]}],"title":"Change from Baseline at Week 1 [N=63; 66; 63]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.734","value":"1.08"},{"groupId":"OG001","spread":"6.506","value":"-1.03"},{"groupId":"OG002","spread":"6.702","value":"8.63"}]}],"title":"Change from Baseline at Week 4 [N=63; 67; 63]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.922","value":"-9.92"},{"groupId":"OG001","spread":"6.621","value":"5.11"},{"groupId":"OG002","spread":"6.972","value":"-3.71"}]}],"title":"Change from Baseline at Week 8 [N=62; 67; 61]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.598","value":"4.65"},{"groupId":"OG001","spread":"11.235","value":"21.13"},{"groupId":"OG002","spread":"11.822","value":"33.22"}]}],"title":"Change from Baseline at Week 12 [N=59; 63; 57]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.702","value":"0.55"},{"groupId":"OG001","spread":"10.190","value":"17.89"},{"groupId":"OG002","spread":"10.598","value":"30.77"}]}],"title":"Change from Baseline at EOT [N=64; 70; 65]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"65"}],"units":"Participants"}],"description":"Healthy micturitions (urinations) result in complete emptying of the bladder. Post Void Residual (PVR) is the volume of urine retained after voiding and was assessed using abdominal ultrasound. An increasing PVR over time is an indicator of abnormal bladder function or detrusor decompensation.\n\nLeast squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.","dispersionType":"Standard Error","groups":[{"description":"Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG001","title":"Mirabegron 50 mg"},{"description":"Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG002","title":"Mirabegron 100 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Safety Analysis set included all participants who received at least one dose of study drug. End of treatment (EOT) analysis includes the last assessment for patients who did not complete the Week 12 visit; N indicates the number of patients included at each time point.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 1, 4, 8 and 12","title":"Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Postvoid Residual Volume (PVR)","type":"SECONDARY","unitOfMeasure":"mL"}